Medical Devices

24 tickers rated Buy in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Merit Medical Systems, Inc.
MMSI·Healthcare
A ★★★★Buy
Current$86.24
Target$102.30
Return+18.6%
Nov 1, 2026

Merit Medical offers durable procedure-driven growth, improving margins, and a discount to historical valuation levels, but competition, acquisition execution, and demanding cash flow expectations remain key risks.

Score
79
ResMed Inc.
RMD·Healthcare
A ★★★★Buy
Current$229.94
Target$254.10
Return+10.5%
Nov 1, 2026

ResMed combines a durable sleep therapy franchise, recurring mask revenue, and high cash returns with a relatively attractive valuation, although evolving treatment alternatives and operating-margin pressure could constrain future earnings growth.

Score
83
DexCom, Inc.
DXCM·Healthcare
A ★★★★Buy
Current$82.29
Target$95.20
Return+15.7%
Nov 1, 2026

Dexcom offers recurring CGM revenue, high capital returns, and substantial long-term diabetes-monitoring growth potential at a compressed historical valuation, although Abbott competition and reimbursement constraints could limit upside.

Score
84
Stryker Corporation
SYK·Healthcare
A ★★★★Buy
Current$291.86
Target$338.10
Return+15.8%
Nov 1, 2026

Stryker combines a durable medical-device franchise, strong cash generation and a historically compressed valuation, but weaker guidance, cybersecurity exposure and acquisition impairments challenge near-term earnings confidence.

Score
81
OSI Systems, Inc.
OSIS·Technology
A ★★★★Buy
Current$199.44
Target$217.74
Return+9.2%
Nov 1, 2026

OSI Systems combines specialized security technology, record backlog, and improving cash generation with attractive long-term demand, although geopolitical delivery delays and working-capital volatility could limit earnings realization.

Score
76
Fortive Corporation
FTV·Technology
A ★★★★Buy
Current$65.23
Target$69.51
Return+6.6%
Oct 31, 2026

Fortive combines durable industrial technology franchises, strong free cash flow, and aggressive buybacks with improving earnings momentum, although healthcare margin pressure and a relatively full valuation constrain near-term upside.

Score
75
Align Technology, Inc.
ALGN·Healthcare
A ★★★★Buy
Current$149.89
Target$195.20
Return+30.2%
Oct 31, 2026

Align Technology combines Invisalign's durable clinical franchise, strong cash flow, and attractive valuation with earnings recovery potential, although clear aligner price competition and weaker scanner demand could constrain growth.

Score
83
IDEX Corporation
IEX·Industrials
A ★★★★Buy
Current$233.84
Target$252.50
Return+8.0%
Oct 31, 2026

IDEX combines high-margin niche industrial franchises, strong cash conversion, and improving organic demand to compound earnings, although premium valuation and acquisition execution risks limit its margin of safety.

Score
75
Teledyne Technologies Incorporated
TDY·Technology
A ★★★★Buy
Current$658.23
Target$742.50
Return+12.8%
Oct 31, 2026

Teledyne combines durable imaging and defense-electronics franchises with strong cash generation and growing demand, but premium valuation and acquisition integration risks limit its margin of safety.

Score
82
GE HealthCare Technologies Inc.
GEHC·Healthcare
A ★★★★Buy
Current$76.42
Target$84.63
Return+10.7%
Oct 30, 2026

GE HealthCare combines a durable medical imaging franchise with expanding diagnostics and software earnings at a moderate valuation, although acquisition integration and hospital capital spending cycles could constrain returns.

Score
82
Danaher Corporation
DHR·Healthcare
A ★★★★Buy
Current$229.75
Target$243.10
Return+5.8%
Oct 23, 2026

Danaher's high-switching-cost life sciences and diagnostics franchises can compound cash flow as bioprocessing demand recovers, but acquisition-related leverage and a demanding valuation limit its margin of safety.

Score
78
Intuitive Surgical, Inc.
ISRG·Healthcare
A ★★★★Buy
Current$443.85
Target$460.56
Return+3.8%
Oct 23, 2026

Intuitive Surgical combines a dominant robotic-surgery ecosystem with recurring procedure revenue and strong cash generation, but its premium valuation and planned instrument-pricing reductions constrain near-term upside.

Score
82